logo

North America Epigenetics Market Size (2024 - 2029)

The North America Epigenetics Market is anticipated to experience significant growth, driven by the increasing prevalence of cancer and heightened investments in research and development. The role of epigenetic modifications in influencing cellular responses related to cancer treatment is a key factor contributing to the expansion of the market. This trend underscores the importance of epigenetics in addressing cancer, thereby propelling the market's growth trajectory during the forecast period.

Home Market Analysis Healthcare Research Biotechnology Research Biotechnology R&D Research Life Science Research Technologies Research Genomics Research North America Epigenetics Market Market Size

Market Size of North America Epigenetics Industry

Market Snapshot
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 20.00 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

North America Epigenetics Market Analysis

The North America Epigenetics Market is expected to register a 20% of CAGR growth during the forecast period. The key contributor to the market is the growing burden of cancer and increasing investments into research and development activities. 

According to the American Cancer Society, in 2020, around 1.8 million new cases will be diagnosed in the United States and about 606,520 people are expected to die due to it. Epigenetics modifications can influence the cellular responses with respect to the apoptosis, cell proliferation and senescence. 

Hence, epigenetics has a very crucial role in cancer treatment and thereby it is expected to boost the market growth over the forecast period.

North America Epigenetics Industry Segmentation

Epigenetics refers to the study of genetic controlling by factors except the DNA sequencing of an individual. It majorly deals with the gene expression. The North America Epigenetics Market is segmented By Product, By Application, By Technology and Geography.

By Product
Instruments
Reagents & Kits
Others
By Applications
Oncology
Autoimmune Diseases
Metabollic Diseases
CNS/Pain Diseases
Cardiovascular Diseases
Others
By Technology
Methylation
Acetylation
Phosphorylation
Others
By Geography
North America
United States
Canada
Mexico
Need A Different Region Or Segment?
Customize Now

North America Epigenetics Market Size Summary

The North America Epigenetics Market is poised for significant expansion, driven by the increasing prevalence of cancer and the rising investments in research and development. Epigenetics plays a pivotal role in cancer treatment by influencing cellular responses such as apoptosis, cell proliferation, and senescence, which is expected to propel market growth. Additionally, the market is anticipated to experience steady growth in the cardiovascular disease segment, as epigenetics is becoming increasingly important in understanding drug responses and assessing risk factors. This relevance is underscored by the high mortality rate of cardiovascular diseases in the United States, highlighting the potential of epigenetics in diagnosis and prognosis.

The market's growth trajectory is further supported by substantial investments in research and development, with significant funding reported by organizations like the Pharmaceutical Research and Manufacturers of America. This financial backing is crucial for advancing epigenetic research and applications, thereby positively impacting the market. Key players in the North America Epigenetics Market include prominent companies such as Abcam PLC, Active Motiff, Diagenode Inc., F. Hoffmann-La Roche Ltd, Illumina Inc., Qiagen N.V., Merck & Co. Inc., ThermoFisher Scientific, and Zymo Research Corporation, all of which are instrumental in driving innovation and market dynamics.

Explore More

North America Epigenetics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Burden of Cancer Diseases

      2. 1.2.2 Increasing Investments into Research and Development Activities

      3. 1.2.3 Rising Epigenetic Applications in Non-oncology Diseases

    3. 1.3 Market Restraints

      1. 1.3.1 Presence of Stringent Regulatory Framework

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Product

      1. 2.1.1 Instruments

      2. 2.1.2 Reagents & Kits

      3. 2.1.3 Others

    2. 2.2 By Applications

      1. 2.2.1 Oncology

      2. 2.2.2 Autoimmune Diseases

      3. 2.2.3 Metabollic Diseases

      4. 2.2.4 CNS/Pain Diseases

      5. 2.2.5 Cardiovascular Diseases

      6. 2.2.6 Others

    3. 2.3 By Technology

      1. 2.3.1 Methylation

      2. 2.3.2 Acetylation

      3. 2.3.3 Phosphorylation

      4. 2.3.4 Others

    4. 2.4 By Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

North America Epigenetics Market Size FAQs

The North America Epigenetics Market is projected to register a CAGR of 20% during the forecast period (2024-2029)

Diagenode Inc., Merck KGaA, Illumina Inc., Active Motiff and Abcam Plc are the major companies operating in the North America Epigenetics Market.

North America Epigenetics Report Snapshots

North America Epigenetics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)